Whalerock Point Partners Has Cut Celgene (CELG) Stake; Navellier & Associates Has Lowered Lam Research Corp. (LRCX) Stake By $1.16 Million

June 27, 2018 - By Annabelle Johnson

Celgene Corporation (NASDAQ:CELG) Logo

Whalerock Point Partners Llc decreased Celgene Corp (CELG) stake by 19.61% reported in 2018Q1 SEC filing. Whalerock Point Partners Llc sold 4,475 shares as Celgene Corp (CELG)’s stock declined 18.51%. The Whalerock Point Partners Llc holds 18,343 shares with $1.64 million value, down from 22,818 last quarter. Celgene Corp now has $56.76B valuation. The stock decreased 0.28% or $0.22 during the last trading session, reaching $78.31. About 4.16 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 27, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 30/05/2018 – Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-star Gamma; 27/03/2018 – BMY: FDA GRANTED OPDIVO COMBO BREAKTHROUGH THERAPY DESIGNATION; 18/04/2018 – U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously; 16/05/2018 – Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Ann; 03/04/2018 – #2 — In sudden revamp, Celgene CEO Alles bids his COO goodbye and looks to regain confidence with management shuffle $CELG; 04/05/2018 – CELGENE CORP SEES 2018 ADJUSTED DILUTED EPS ABOUT $8.45, WITH DILUTION FROM JUNO; 15/05/2018 – X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 15/05/2018 – Celgene Presenting at Bank of America Conference Tomorrow; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer

Navellier & Associates Inc decreased Lam Research Corp. (LRCX) stake by 31.12% reported in 2018Q1 SEC filing. Navellier & Associates Inc sold 5,709 shares as Lam Research Corp. (LRCX)’s stock rose 1.81%. The Navellier & Associates Inc holds 12,638 shares with $2.57 million value, down from 18,347 last quarter. Lam Research Corp. now has $28.53B valuation. The stock increased 1.71% or $2.92 during the last trading session, reaching $173.93. About 3.39M shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 31.27% since June 27, 2017 and is uptrending. It has outperformed by 18.70% the S&P500. Some Historical LRCX News: 06/03/2018 – LAM RESEARCH: ADDED $2B SHARE BUYBACK; 06/03/2018 – Lam Research: Capital Return Plan Includes 120% Increase of Qtrly Div; 17/04/2018 – LAM RESEARCH CORP SEES FOR JUNE 2018 QTR, U.S. GAAP SHIPMENTS $3.000 BLN +/- $150 MLN; 18/04/2018 – LAM RESEARCH CORP LRCX.O : CREDIT SUISSE RAISES TARGET PRICE TO $278 FROM $275; 17/05/2018 – Lam Research Corporation Declares Quarterly Dividend; 06/03/2018 – LAM RESEARCH CORP – ADDITIONAL $2 BLN SHARE REPURCHASE AUTHORIZATION FOR A TOTAL OF $4 BLN AUTHORIZED SINCE NOVEMBER 2017; 30/04/2018 – Alger Capital Appreciation Institutional Adds Lam Research; 22/04/2018 – DJ Lam Research Corporation, Inst Holders, 1Q 2018 (LRCX); 24/04/2018 – Lam Research Closes Below 200-Day Moving Average: Technicals; 06/03/2018 – Lam Research Corp Announces Cap Return Program

Investors sentiment increased to 1.1 in 2018 Q1. Its up 0.02, from 1.08 in 2017Q4. It is positive, as 62 investors sold LRCX shares while 259 reduced holdings. 131 funds opened positions while 223 raised stakes. 138.23 million shares or 1.88% less from 140.89 million shares in 2017Q4 were reported. Point72 Asset Management Limited Partnership has 731,287 shares for 0.62% of their portfolio. 1.86 million were reported by Pointstate Cap Limited Partnership. Guinness Asset Mgmt Ltd holds 30,070 shares. Allsquare Wealth Mngmt Ltd Limited Liability Company has invested 0.03% in Lam Research Corporation (NASDAQ:LRCX). Spectrum Mngmt Grp invested in 150 shares or 0.01% of the stock. Wisconsin-based First Business Finance Ser Inc has invested 0.16% in Lam Research Corporation (NASDAQ:LRCX). Moreover, Amundi Pioneer Asset has 0.15% invested in Lam Research Corporation (NASDAQ:LRCX). Scotia has 0.01% invested in Lam Research Corporation (NASDAQ:LRCX) for 3,325 shares. Acadian Asset Limited Liability Co holds 0.48% or 543,837 shares in its portfolio. Adage Limited Co has 0.23% invested in Lam Research Corporation (NASDAQ:LRCX). Selz Ltd Limited Liability Company holds 3.31% of its portfolio in Lam Research Corporation (NASDAQ:LRCX) for 105,800 shares. 9,079 were accumulated by Amica Pension Fund Board Of Trustees. Central Asset Invs And Mgmt (Hk) Ltd owns 42,700 shares for 7.42% of their portfolio. Cleararc Cap Inc accumulated 4,181 shares or 0.13% of the stock. Pnc Financial Service Grp Inc reported 0.14% stake.

More notable recent Lam Research Corporation (NASDAQ:LRCX) news were published by: 247Wallst.com which released: “Why Nvidia Still Trumps AMD, Intel and Other Chip Names at Current Prices” on June 26, 2018, also Investorplace.com with their article: “20 Massively Underpriced Stocks Wall Street Expects to Soar” published on June 25, 2018, Seekingalpha.com published: “Lam Research Is A Huge Buy” on June 13, 2018. More interesting news about Lam Research Corporation (NASDAQ:LRCX) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: AMC Networks, Kinder Morgan, Lam Research, MGM Resorts, Spotify and More” published on June 26, 2018 as well as Investorplace.com‘s news article titled: “5 All-Star Dividend Stocks for Any Portfolio” with publication date: June 26, 2018.

Since January 23, 2018, it had 0 insider purchases, and 12 selling transactions for $28.53 million activity. $2.24M worth of Lam Research Corporation (NASDAQ:LRCX) was sold by O’Dowd Sarah A on Thursday, March 22. LORD PATRICK J sold $1.20M worth of Lam Research Corporation (NASDAQ:LRCX) on Friday, April 20. 11,200 shares were sold by Anstice Martin B, worth $2.52M on Wednesday, March 21. 16,866 shares valued at $3.54M were sold by Gottscho Richard A on Wednesday, March 7. On Friday, March 9 the insider ARCHER TIMOTHY sold $1.39 million. The insider Varadarajan Seshasayee sold 25,453 shares worth $5.47M.

Navellier & Associates Inc increased Sony Corp. (NYSE:SNE) stake by 22,985 shares to 49,776 valued at $2.41 million in 2018Q1. It also upped Ishares Dow Jones U.S. Technol (IYW) stake by 43,974 shares and now owns 67,736 shares. Ecopetrol S.A. Ads (NYSE:EC) was raised too.

Analysts await Lam Research Corporation (NASDAQ:LRCX) to report earnings on July, 25. They expect $5.00 EPS, up 60.77% or $1.89 from last year’s $3.11 per share. LRCX’s profit will be $820.22M for 8.70 P/E if the $5.00 EPS becomes a reality. After $4.79 actual EPS reported by Lam Research Corporation for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

Among 27 analysts covering Lam Research Corporation (NASDAQ:LRCX), 26 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation has $305.0 highest and $52 lowest target. $250.58’s average target is 44.07% above currents $173.93 stock price. Lam Research Corporation had 98 analyst reports since September 17, 2015 according to SRatingsIntel. JP Morgan maintained it with “Overweight” rating and $260 target in Thursday, January 25 report. On Monday, May 16 the stock rating was maintained by Cowen & Co with “Outperform”. The stock has “Overweight” rating by Morgan Stanley on Tuesday, December 15. The stock of Lam Research Corporation (NASDAQ:LRCX) earned “Buy” rating by Stifel Nicolaus on Thursday, January 25. KeyBanc Capital Markets maintained Lam Research Corporation (NASDAQ:LRCX) rating on Wednesday, March 7. KeyBanc Capital Markets has “Overweight” rating and $276 target. RBC Capital Markets maintained Lam Research Corporation (NASDAQ:LRCX) rating on Wednesday, August 30. RBC Capital Markets has “Buy” rating and $185.0 target. The rating was maintained by UBS with “Buy” on Monday, June 5. As per Thursday, October 19, the company rating was maintained by Argus Research. On Thursday, January 26 the stock rating was maintained by Needham with “Buy”. The company was maintained on Thursday, January 25 by Morgan Stanley.

Since February 8, 2018, it had 2 insider buys, and 5 sales for $5.91 million activity. 1,208 shares valued at $99,784 were bought by Alles Mark J on Tuesday, May 8. KAPLAN GILLA had sold 18,500 shares worth $1.77 million on Thursday, February 15. The insider LOUGHLIN JAMES J sold $851,093. MARIO ERNEST sold $1.26M worth of Celgene Corporation (NASDAQ:CELG) on Friday, February 23. $1.02M worth of stock was sold by CASEY MICHAEL D on Thursday, June 7.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “2 Incredibly Cheap Value Stocks to Buy Now” on June 22, 2018, also Seekingalpha.com with their article: “Finger-Pointing At Celgene” published on June 14, 2018, Seekingalpha.com published: “5 Reasons Why Celgene Will Recover” on June 01, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Fool.com and their article: “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” published on June 24, 2018 as well as Nasdaq.com‘s news article titled: “Why I’m Bullish on the Riskiest Big Biotech Stock on the Market” with publication date: June 21, 2018.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 21 have Buy rating, 1 Sell and 13 Hold. Therefore 60% are positive. Celgene Corporation has $190 highest and $83 lowest target. $127.48’s average target is 62.79% above currents $78.31 stock price. Celgene Corporation had 151 analyst reports since July 21, 2015 according to SRatingsIntel. JMP Securities maintained it with “Market Outperform” rating and $152 target in Wednesday, March 9 report. Leerink Swann maintained it with “Buy” rating and $11500 target in Monday, May 7 report. Canaccord Genuity maintained Celgene Corporation (NASDAQ:CELG) on Tuesday, January 23 with “Buy” rating. As per Thursday, January 7, the company rating was initiated by SunTrust. The firm earned “Buy” rating on Thursday, October 26 by Cowen & Co. The firm has “Buy” rating by Standpoint Research given on Thursday, January 14. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, July 27 by Cowen & Co. On Thursday, May 31 the stock rating was maintained by Cantor Fitzgerald with “Hold”. Oppenheimer maintained Celgene Corporation (NASDAQ:CELG) on Thursday, July 6 with “Buy” rating. BMO Capital Markets maintained Celgene Corporation (NASDAQ:CELG) on Friday, July 28 with “Outperform” rating.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 26. They expect $1.87 EPS, up 11.31% or $0.19 from last year’s $1.68 per share. CELG’s profit will be $1.36 billion for 10.47 P/E if the $1.87 EPS becomes a reality. After $1.61 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 16.15% EPS growth.

Lam Research Corporation (NASDAQ:LRCX) Institutional Positions Chart